[Efficacy of pneumococcal vaccination].
POLYVALENT VACCINE: Pneumococcal vaccination is based on the antigenic properties of polysides carried on the bacterial capsule which induce production of bactericidal serotype-specific antibodies. The 23 serotypes contained in the current vaccine cover 85 to 90% of all strains observed in pneumococcal infections in Europe.
Prospective and retrospective studies have demonstrated that pneumococcal vaccination can prevent 60 to 80% of invasive pneumococcal infections in immunocompetent elderly subjects and/or persons in high-risk groups with underlying disorders.


METHODS
Immunocompetent persons in the 60-65 year and older age group comprise the target population for pneumococcal vaccination. Incidence and mortality of pneumococcal infections is high in this group. Simple vaccination strategies should be implemented.
Hessel
L
L
Pasteur Mérieux MSD, Lyon.
D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000276:immunology / Q000517:prevention & control; D001428:Bacterial Vaccines; D005602:France / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D011018:Pneumonia, Pneumococcal / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D011446:Prospective Studies; D012189:Retrospective Studies; D018074:Vaccines, Conjugate
D001428:Bacterial Vaccines; D018074:Vaccines, Conjugate
Efficacité de la vaccination pneumococcique.